Sandy Primrose is a biologist who has a very varied career. This includes being an academic undertaking research, a senior manager in the pharmaceutical, biotechnology and diagnostics industries, managing programmes for government on detection of food fraud and the safety of genetically modified foods, chairman of various early-stage companies and non-executive director of various government bodies.
About Us
Our mission is to generate novel molecular insights that transform drug development and healthcare globally.
We deliver highly accurate, fully quantitative and definitive targeted biomarker analysis to accelerate the development of life-changing treatments.
The Inoviv Team
Dr Sandy Primrose
Chair
Dr Marie Labus
Chief Executive Officer
Marie holds a PhD from University of Aberdeen and is...
Dr Marie Labus
Chief Executive Officer
Marie holds a PhD from University of Aberdeen and is a seasoned life science executive with over 25 years of experience leading C-suite operations and scaling SMEs. Marie has a distinguished track record in translating academic innovation into commercial success, having managed University spin-outs from conception to exit through acquisition, launched a diagnostic product into the US market, and navigated complex intellectual property, licensing, and international R&D activities. Her leadership has been instrumental in securing investment from Tier-1 venture capital firms including Esperante Ventures, Ascension VC, Hoxton Ventures and Foresight Group. As CEO of Inoviv, she leads the company’s mission to transform drug development through highly accurate, fully quantitative proteomics. Marie is a prominent advocate for women in the UK life sciences ecosystem and sits on the board of The Whole Point Newcastle.
Susan Robson
Chief Financial Officer
Susan is a highly experienced finance professional with over 20...
Susan Robson
Chief Financial Officer
Susan is a highly experienced finance professional with over 20 years in the field and is a CIMA-qualified accountant who has led finance functions across the pharmaceutical, technology, and software sectors. Her expertise includes strategic financial leadership, long-term business planning, and robust financial modelling, alongside experience in mergers and acquisitions. She has a strong track record in business turnaround and transformation, delivering successful restructuring initiatives and building high-performing, engaged finance teams.
Jane Meaney
Chief Marketing Officer
Jane holds an MBA and BSc in Biology and is also a Fellow of the Chartered Institute of Marketing (FCIM). She has over 35 years commercial experience in life science businesses, latterly specialising in diagnostics start-ups and spin-outs. She has a track record of bringing academic or science-based start-ups into initial commercial success. This is achieved with forensic examination of the issues and the experience to leverage her deep marketing knowledge to create strategies and messaging to positioning and sell products to the right audiences. For the last 5 years Jane has held C-suite marketing positions on company boards, which included launching new products in the USA and UK and managing contract sales team relationships. Jane’s role as CMO at Inoviv is to scale sales by redefining and rebuilding the commercial function. She also sits on the executive board of BIVDA.
Martin Bachman
Chief Technical Officer
Martin is an accomplished professional with extensive experience in bioanalysis...
Martin Bachman
Chief Technical Officer
Martin is an accomplished professional with extensive experience in bioanalysis and mass spectrometry. Currently serving as the Director of Bioanalysis at Inoviv, Martin brings a wealth of knowledge and expertise to his role. Prior to joining Inoviv, Martin served as Lead Scientist at Medicines Discovery Catapult, where he established a high-throughput mass spectrometry laboratory and played a key role in developing innovative solutions for complex analytical challenges in drug discovery and biomarker research. Martin also contributed to innovative projects as a Postdoctoral Scientist at AstraZeneca, where he played a pivotal role in the design and development of Acoustic Mist Ionisation MS (AMI-MS), a cutting-edge analytical platform that revolutionized drug discovery efforts.
Dr Colin Brown
Scientific Director
Colin Brown received his Bachelor and Ph.D degrees in Physiology...
Dr Colin Brown
Scientific Director
Colin Brown received his Bachelor and Ph.D degrees in Physiology and Pharmacology from the University of St Andrews, Scotland. He then held a Royal Society European Postdoctoral Fellowship, focusing on renal phosphate transport, at the Institute of Physiology, University of Zurich, Switzerland. After this Colin was awarded a Wellcome Trust Senior Research Fellowship at University of Manchester UK. Following on from this Colin was an Associate Professor at the University of Newcastle for nearly 30 years. In 2017 Colin joined Newcells Biotech as CSO. Dr Brown’s research interests have centered around the study of the interaction of drug molecules with transport proteins in renal, hepatic and gastrointestinal epithelia. Dr Brown is a Key Opinion Leader on drug transport and drug toxicity in kidney. His group developed the aProximate platform, a series of highly differentiated proximal tubule primary culture models that have proven highly effective in understanding drug transport, the impact of drug–drug interactions on proximal tubule drug clearance and as a highly predictive screen of nephrotoxicity using clinically relevant biomarkers as measures of toxicity. Dr Brown has published widely in the field of drug transporter studies and toxicity and consults frequently with the pharmaceutical industry.
Blandine Rougemont
Associate Director, Bioanalysis
Blandine is a seasoned professional with over a decade of...
Blandine Rougemont
Associate Director, Bioanalysis
Blandine is a seasoned professional with over a decade of experience in protein analysis and quantification via mass spectrometry. She has worked across diverse industries including diagnostics, pharmaceuticals, and agriculture. Before joining Inoviv as associate director of Analysis, she held technical expert roles in various companies such as BioMerieux, Sanofi Pasteur, UCB Pharma, and Syngenta. Her expertise lies in utilizing targeted and global proteomics quantitative workflows to identify biomarkers, metabolic pathways, and mechanisms of action for new molecules. Notable highlights of her career include her doctoral research at Université Claude-Bernard-Lyon-I, focusing on targeted proteomics for vaccine integrity monitoring in collaboration with Sanofi Pasteur, and her work with Sciex on novel approaches for highly multiplexed targeted mass spectrometry datasets.
Rob Kniaz
Partner — Hoxton Ventures
Rob is a partner at Hoxton Ventures, one of the earliest backers of unicorn startups including Deliveroo, Babylon Health and DarkTrace, and joins Inoviv as an investor director. A dual US/UK national, he holds a BS in Computer Science from the University of Maryland and a Masters certificate in Management Science & Engineering from Stanford University.
Danielle Gubbay
Investor Observer — Foresight Group
Danielle is a Senior Investment Manager from Foresight Group and...
Danielle Gubbay
Investor Observer — Foresight Group
Danielle is a Senior Investment Manager from Foresight Group and recently joined Inoviv as an Investor Observer. She is an experienced entrepreneur (ex-CEO) and has invested in multiple early-stage businesses across industries. Danielle holds a BEc from the University of Sydney and a Juris Doctorate from the University of Technology, Sydney.
Our expert team is here to help your drugs work better.
Collaborations and Partnerships
Our solutions are the trusted choice for biotechnology and pharmaceutical organizations globally
We are Backed By
